/ Hogar / Centro de productos / Intermediarios avanzados / Anti-Cáncer /

Ruxolitinib Intermediate

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Número de CAS
941678-49-5
Fórmula Molecular
C17H18N6
Peso Molecular
306.37
Pureza
98%
Indicación
Ruxolitinib Intermediate
Descripción del Producto

In November 2011, the U.S. FDA approved ruxolitinib (INCB018424) for the treatment of patients with intermediate or high-risk myelofibrosis. Ruxolitinib is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50's of 3.3±1.2 nM and 2.8±1.2 nM